Unibest
← Back to patent-cliff list

Bupropion hydrobromide

Tier C — Watch / trade

Bupropion hydrobromide

Valeant
Originator
2008
First approval
-
Expiry (public)
$0.11B ▲
Peak sales
Small molecule
Type

Targets:NET, DAT, Adrenoceptors

Brand:Aplenzin

Indications (approved):Seasonal affective disorder, Major depressive disorder

Regional status

US
Approved
2008-04-23
EU
No progress
2006-05-01
China
-
Japan
-

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Sign in to view factories →

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Bupropion hydrobromide?

Approved indications include: Seasonal affective disorder, Major depressive disorder.

When does the Bupropion hydrobromide patent expire?

No public expiry year is available for Bupropion hydrobromide yet; this page updates once verified.

How do I get a quote for Bupropion hydrobromide intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29